These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3770056)

  • 1. Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.
    Cummings J; Milstead R; Cunningham D; Kaye S
    Eur J Cancer Clin Oncol; 1986 Aug; 22(8):991-1001. PubMed ID: 3770056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing ridgway osteogenic sarcoma (ROS).
    Cummings J; Merry S; Willmott N
    Eur J Cancer Clin Oncol; 1986 Apr; 22(4):451-60. PubMed ID: 3460809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.
    Cummings J; Kerr DJ; Kaye SB
    Cancer Chemother Pharmacol; 1987; 20(3):263-4. PubMed ID: 3677300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.
    Cummings J; Stuart JF; Calman KC
    J Chromatogr; 1984 Nov; 311(1):125-33. PubMed ID: 6520153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Method for the determination of 4'-deoxydoxorubicin, 4'-deoxydoxorubicinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.
    Cummings J
    J Chromatogr; 1985 Jun; 341(2):401-9. PubMed ID: 4030989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].
    Ehninger G; Stocker HJ; Proksch B; Wilms K
    Klin Wochenschr; 1980 Sep; 58(18):927-34. PubMed ID: 7206588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilary disposition of adriamycin.
    Riggs CE; Benjamin RS; Serpick AA; Bachur NR
    Clin Pharmacol Ther; 1977 Aug; 22(2):234-41. PubMed ID: 884924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues.
    Cummings J; Willmott N; More I; Kerr DJ; Morrison JG; Kaye SB
    Biochem Pharmacol; 1987 May; 36(9):1521-6. PubMed ID: 3579988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.
    Israel M; Wilkinson PM; Pegg WJ; Frei E
    Cancer Res; 1978 Feb; 38(2):365-70. PubMed ID: 620407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites.
    Preiss R; Sohr R; Kittelmann B; Müller E; Haase D
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):156-64. PubMed ID: 2714916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of doxorubicin, (2"R)-4'-O-tetrahydropyranyl-adriamycin and aclarubicin.
    Fujita H; Ogawa K; Tone H; Iguchi H; Shomura T; Murata S
    Jpn J Antibiot; 1986 May; 39(5):1321-36. PubMed ID: 3463778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.
    Han G; Israel M; Seshadri R; Dalton JT; Sweatman TW
    Cancer Chemother Pharmacol; 1996; 37(5):472-8. PubMed ID: 8599871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition and metabolism of adriamycin in the rat.
    Tavoloni N; Guarino AM
    Pharmacology; 1980; 21(4):244-55. PubMed ID: 7422708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
    Greene RF; Collins JM; Jenkins JF; Speyer JL; Myers CE
    Cancer Res; 1983 Jul; 43(7):3417-21. PubMed ID: 6850648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.
    Bolanowska W; Gessner T; Preisler H
    Cancer Chemother Pharmacol; 1983; 10(3):187-91. PubMed ID: 6574828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.
    Benjamin RS; Riggs CE; Bachur NR
    Cancer Res; 1977 May; 37(5):1416-20. PubMed ID: 856462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol.
    Leca F; Marchiset-Leca D; Noble A; Antonetti M
    Eur J Drug Metab Pharmacokinet; 1991; 16(2):107-11. PubMed ID: 1936069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mathematical model for adriamycin (doxorubicin) pharmacokinetics.
    Reich SD; Steinberg F; Bachur NR; Riggs CE; Goebel R; Berman M
    Cancer Chemother Pharmacol; 1979; 3(2):125-31. PubMed ID: 509697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of adriamycin and its fluorescent metabolites in human plasma by HPLC.
    Mahdadi R; Lhermitte M; Lafitte JJ
    Biomed Chromatogr; 1987 Feb; 2(1):38-40. PubMed ID: 3508093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition and metabolism of adriamycin octanoylhydrazone (NSC 233853) in mice and rabbits.
    Egorin MJ; Clawson RE; Ross LA; Chou FT; Andrews PA; Bachur NR
    Drug Metab Dispos; 1981; 9(3):240-5. PubMed ID: 6113933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.